Yesterday it was reported that a Director at Jazz Pharmaceuticals (JAZZ – Research Report), Catherine Sohn, exercised options to sell 12,500 JAZZ shares at $59.40 a share, for a total transaction value of $1.92M.
Following Catherine Sohn’s last JAZZ Sell transaction on August 10, 2020, the stock climbed by 22.4%.
Based on Jazz Pharmaceuticals’ latest earnings report for the quarter ending June 30, the company posted quarterly revenue of $562 million and quarterly net profit of $115 million. In comparison, last year the company earned revenue of $538 million and had a net profit of $102 million. The company has a one-year high of $158.98 and a one-year low of $86.88. Currently, Jazz Pharmaceuticals has an average volume of 335.32K.
Based on 11 analyst ratings, the analyst consensus is Strong Buy with an average price target of $183.64, reflecting a -17.3% downside.
The insider sentiment on Jazz Pharmaceuticals has been negative according to 64 insider trades in the past three months. This sentiment is lower than the average sentiment of company insiders in this sector.
Catherine Sohn’s trades have generated a -7.4% average return based on past transactions. DailyInsider proprietary algorithm detects trades by the most influential insiders and selects attractive trading opportunities daily. To subscribe to the DailyInsider visit this page.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Jazz Pharmaceuticals Plc operates as a specialty biopharmaceutical company, which focuses on the identification, development and commercialization of pharmaceutical products in the areas of narcolepsy, oncology, pain and psychiatry. Its product portfolio includes: XYREM, ERWINAZETM, PRIALT, intrathecal infusion, FAZACLO and LUVOX CR. The company was founded by Bruce C. Cozadd in March 2003 and is headquartered in Dublin, Ireland.